Composition specification of teicoplanin based on its estimated relative bioavailability

References

• Borghi A, Edwards D, Zerilli LF, Lancini GC. Factors affecting the normal and branched-chain acyl moieties of teicoplanin components produced by Actinoplanes teichomyceticus. J Gen Microbiol 1991;137:587–92
   PubMedGoogle Scholar
• European committee on antimicrobial susceptibility testing. Eucast recommended strains for internal quality control. v.1.3. (December 2010). Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_QC_Tables_V1.0.pdf [last accessed Feb 2013]
   Google Scholar
• Verbist L, Tjandramaga B, Hendrickx B, et al. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother 1984;26:881–6
   PubMed Web of Science ®Google Scholar
• European Council. European Pharmacopoeia corrected 6.6. Teicoplanin monograph (01/20092358). Available from: http://www.edqm.eu/en/european-pharmacopoeia-publications-1401.html [last accessed Nov 2012]
   Google Scholar
• Japanese Ministry of Health, Labour and Welfare, Japanese Pharmacopoeia Sixteenth Edition, Teicoplanin monograph (2012). Available from: http://jpdb.nihs.go.jp/jp16e/JP16.pdf [last accessed Nov 2012]
   Google Scholar
• Rowland M. Clinical pharmacokinetics of Teicoplanin. Clin Pharmacokinet 1990;18:184–209
   PubMed Web of Science ®Google Scholar
• Borghi A, Coronelli C, Faniuolo L, et al. Teichomycins, new antibiotics from Actinoplanes Teichomyceticus nov. Sp. IV. Separation and characterization of the components of Teichomycin (Teicoplanin). J Antib 1984;37:615–20
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Questions and answers on the referal for teicoplanin Hospira powder and solvent for injection containing 200 or 400 mg teicoplanin (2009) EMA/CHMP/77992/2010. EMEA/H/A-29/1084. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/Referrals_document/Teicoplanin_Hospira_29/WC500014116.pdf [last accessed 17 Feb 2013]
   Google Scholar
• Fujimura S, Fuse K, Takane H, et al. Antibacterial effects of brand-name teicoplanin and generic products against clinical isolates of methicillin-resistant Staphylococcus aureus. J Infect Chemother 2011;17:30–3
   PubMed Web of Science ®Google Scholar
• Bernareggi A, Borghi A, Borgonovi M. Teicoplanin metabolism in humans. Antimicrob Agents Chemother 1992;36:1744–9
   PubMed Web of Science ®Google Scholar
• Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 1990;39:167–83
   Web of Science ®Google Scholar
• Bernareggi A, Danese A, Cometti A, et al. Pharmacokinetics of individual components of teicoplanin in man. J Pharmacokinet Biopharm 1990;18:525–43
   PubMedGoogle Scholar
• Falcoz C, Ferry N, Pozet N, et al. Pharmacokinetics of teicoplanin in renal failure. Antimicrob Agents Chemother 1987;31:1255–62
   PubMed Web of Science ®Google Scholar
• Hanada K, Kobayashi A, Okamori Y, et al. Improved quantitative determination of total and unbound concentrations of six teicoplanin components in human plasma by high performance liquid chromatography. Biol Pharm Bull 2005;28:2023–5
   PubMed Web of Science ®Google Scholar
• Hanada K, Ikari S, Koukaki Y, et al. Comparison of pharmacokinetics of individual teicoplanin components in patients. Biol Pharm Bull 2007;30:952–4
   PubMed Web of Science ®Google Scholar
• Riva E, Ferry N, Cometti A, et al. Determination of teicoplanin in human plasma and urine by affinity and reversed-phase high-performance liquid chromatography. J Chrom 1987;421:99–110
   PubMed Web of Science ®Google Scholar
• Certara – Pharsight software. WinNonlin v. 5.3. Available from: www.certara.com [last accessed 6 Feb 2014]
   Google Scholar
• European Medicines Agency. Guideline on the investigation of bioequivalence (2010) CPMP/EWP/QWP/1401/98 Rev. 1/Corr. Availabe at: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf [last accesed 17 Feb 2013]
   Google Scholar
• Vesga O, Agudelo M, Salazar BE, et al. Generic Vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother 2010;54:3271–9
   PubMed Web of Science ®Google Scholar
• Gould IM, David MZ, Esposito S, et al. New insights into methicillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrobial Agents 2012;39:96–104
   PubMed Web of Science ®Google Scholar
• International Standardization Organization. Clinical laboratory testing and in vitro diagnostic test systems – susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices – Part 1 Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. ISO 20776-1:2006
   Google Scholar
• Barry AL, Jones RN, Gavan TL, Thornsberry C. The collaborative antimicrobial susceptibility testing group. Quality control limits for teicoplanin susceptibility tests and confirmation of disk diffusion interpretative criteria. J Clin Microbiol 1987;25:1812–14
   PubMedGoogle Scholar
• Guerin F, Buu-Hoi A, Mainardi JL, et al. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian Hospital. J Clin Microbiol 2000;28:2985–8
   Google Scholar
• Vaudaux P, Huggler E, Bernard L, et al. Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus. Antimicrob Agents Chemother 2010;54:3861–70
   PubMed Web of Science ®Google Scholar
• Zuluaga AF, Agudelo M, Rodríguez CA, Vesga O. Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics. BMC Clin Pharmacol 2009;9:1–11
   PubMedGoogle Scholar
• Antúnez S, Niubó C, Carro AM, et al. Validación de métodos de análisis en microbiología. In: Pérez Cuadrado JA, Pujol Forn M, eds. Validación de métodos analíticos. Barcelona: AEFI; 2001:135–208. Spanish
   Google Scholar
• Reed MD, Yamishita TS, Myers CM, Blumer JL. The pharmacokinetics of Teicoplanin in infants and children. J Antimicrob Chemother 1997;39:789–96
   PubMed Web of Science ®Google Scholar
• Mochizuki N, Ohno K, Shimamura T, et al. Quantitative determination of individual teicoplanin components in human plasma and cerebrospinal fluid by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007;847:78–81
   PubMed Web of Science ®Google Scholar
• Firsov AA, Lubenko IY, Vosrov SN, et al. Antistaphylococcal effect related to the area Ander the curve/MIC ratio in an in vitro dynamic model predicted breakpoints versus clinically achievable values for seven fluoroquinolones. Antimicrob Agents Chemother 1995;49:2642–7
   Web of Science ®Google Scholar
• Hagihara M, Umemura T, Kimura M, et al. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus. J Infect Chemother 2012;18:10–16
   PubMed Web of Science ®Google Scholar
• Fujimura S, Watanabe A. Generic antibiotics in Japan. J Infect Chemother 2012;18:421–7
   PubMed Web of Science ®Google Scholar